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Abstract: A positive patient experience has been long
recognised as a key feature of a high-quality health service,
however, often assessment of patient experience excludes
diagnostic care. Experience of diagnostic services and the
acceptability of diagnostic tests are often conflated, with
lack of clarity about when and how either should be
measured. These problems contrast with the growth in the
development andmarketing of new tests and investigation
strategies. Building on the appraisal of current practice, we
propose that the experience of diagnostic services and the
acceptability of tests should be assessed separately, and
describe distinct components of each. Such evaluations
will enhance the delivery of patient-centred care, and
facilitate patient choice.
Keywords: acceptability; diagnostic care; investigations;
patient-centred care; patient experience.
Introduction
Patient-centred care is a core aim of health systems, which
includes regarding patients as integral participants in the
diagnostic process [1]. However the importance of patient
experience of diagnostic services, and acceptability of in-
vestigations is still inadequately considered. Where they
are considered, the experience of diagnostic services is
often conflated with the acceptability of diagnostic tests.
We outline the key components and correlates of either
concept, and illustrate how they can be assessed.
Conceptualising patient experience
of diagnostic services
Recognition of the importance of patient experience,
defined as ‘… the sum of all interactions, shaped by an
organization’s culture, that influence patient perceptions
across the continuum of care’, as a distinct dimension of
care quality has increased over the last two decades [2].
Building on pioneering work by the Picker Institute [3],
NICE (the English National Institute for Health and Social
Care Excellence, aUK evidence-based, andpatient-focused
guideline producing organisation) distinguishes five di-
mensions of patient experience, that are appropriate for
guiding the assessment of experience of diagnostic ser-
vices with some modifications [4]. We also propose a sixth
and seventh dimension:
1) Patient-centred care: opportunities to discuss concerns
and preferences. For example, ‘I was given the chance to
discuss my concerns about the test’;
2) Essential requirements of care: physical and psycho-
logicalneedsassessedandaddressed, aswell aspatients
being treated with dignity, kindness and respect. For
example, ‘I was treated with dignity and respect during
testing’ or ‘my test result was delivered sensitively’;
3) Tailored healthcare: care is designed around patients’
needs and preferences. For example, ‘I was given a
choice about when I had my test done’;
4) Continuity and coordination of care, including quality
and safety. For example, ‘My doctor knew important in-
formation about my medical history’ or ‘I knew when I
should have the results of my test’;
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5) Shared decision-making and informed choice about
testing; including communication of uncertainty. For
example, ‘I felt I had an understanding of the benefits of
the test’;
Novel dimensions that should be considered are:
6) Waiting times: consideration of time waiting between
test ordering, performance (including waiting for an
appointment) and results [5, 6]. For example, ‘I did not
have to wait long before going in to my appointment’.
7) Service environment: assessment of the quality of
diagnostic service facilities [7], quality of transport
links, and availability of parking, where required. For
example, ‘I was satisfied with the cleanliness of the
testing clinic’.
Although the nature of the test result is more relevant to
patients’ disease experience, it should be noted that it may
confound the testing experience.
Good practice in measuring patient
experience of diagnostic services
Evaluating experience of diagnostic services should
encompass all aspects/phases of the diagnostic care
pathway, including referral, communication of diagnostic
information, performance, and assessment. Robust
nationwide measurement of experience of diagnostic ser-
vices can inform policy decisions and guide patient choice
between different diagnostic care providers. However,
major patient survey initiatives such as the US Consumer
Assessment of Healthcare Providers and Systems program
(CAHPS) or the UK General Practice Patient Survey (GPPS)
do not adequately address the experience of diagnostic
testing. Therefore, developing psychometrically valid
items, covering key concepts proposed, and incorporating
them into patient surveys is important. As a starting point,
service experience items from existing surveys such as
CAHPS and GPPS could be modified for diagnostic care.
Although single item example questions are provided
above, multiple items will be needed to cover all key facets
of experience relating to each dimension.
Assessing patient experience of diagnostic services for
quality improvement can be particularly helpful in elective
(non-acute) care contexts, where the potential for informed
decision-making and patient choice are greatest. For
example, assessment of the ‘service environment’ of
testing could identify that the testing location is difficult for
patients to get to, resulting in a change towhere the service
is offered, and reducing non-attendances. Assessment of
experience of diagnostic services can also help to under-
stand potential patient group inequalities in experience
of diagnostic care [8], to determine patients at greater
risk of poorer experience, guiding the development of
interventions.
Conceptualising patient
acceptability of diagnostic tests
While examining the experience of diagnostic services is
important, the acceptability of diagnostic tests should be
considered separately. Previous work to assess test expe-
rience has focused on partial aspects such as physical and
psychological discomfort [7, 9–11], or global satisfaction [7,
11–13]. We propose that test experience can be measured
more systematically and comprehensively by its ‘accept-
ability’ as a special type of healthcare intervention.
Sekhon et al. propose that acceptability of health care
interventions is defined as ‘a reflection of the extent to which
people receiving a healthcare intervention consider it to be
appropriate, based on anticipated or experiential cognitive
and emotional responses to the intervention’ [14]. They
suggest that acceptability comprises seven facets: affective
attitude, burden, ethicality, intervention coherence, op-
portunity costs, perceived effectiveness and self-efficacy
[14]. According to this framework, acceptability can be
measured prospectively (in advance of undergoing the
test), retrospectively (following the test) and concurrently
(while undergoing the test). Clarity is however required
about applying facets of acceptability in the context of
diagnostic tests (Table 1).
– ‘Affective attitude’ can represent a global measure of
accepting the test e.g. ‘I would like to have the test’.
– ‘Test burden’ encompasses physical andpsychological
discomfort during and after the test, psychological
distress experienced before it and, in the case of a
negative test in particular, relief after it. For example, ‘I
experienced pain after the test’. It can also incorporate
time burden (travel time, time away from the family).
– ‘Test coherence’ reflects the patient’s understanding of
why the test is being done given their symptoms/
context. This will depend on information provision
and health literacy. For example, ‘I felt I had a good
understanding of why the test was being done’.
– ‘Perceived test effectiveness’ assesses whether pa-
tients think the test is right for their situation and
whether the test will give an accurate result. It will vary
by the test’s purpose (e.g. whether for ruling in or out a
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condition, or to guide management or to assess prog-
nosis), and by patient experience (e.g. how well un-
certainty has been communicated). For example, ‘I felt
the test would help give me an accurate diagnosis’.
– ‘Self-efficacy’ comprises the patient’s confidence that
they can physically and cognitively complete the test.
For example, ‘It was easy for me to do the test’.
The concepts of ‘opportunity costs’ and ‘ethicality’ require
further elaboration for the testing context:
– ‘Opportunity costs’ are defined by Sekhon in line with
health economics literature [14]. In the context of testing it
should refer to costs of having the test, including paying
for the test (fee-for-service) andhaving to takeunpaid time
off work. It may also refer to individuals being unable to
do the test because of cost. This dimension may be var-
iably applicable depending on different healthcare sys-
tems and insurance schemes. For example, ‘I had to take
unpaid time off work to have the test’.
– Ethicality encompasses whether the test meets pa-
tients’ ideological, religious or political beliefs. For
example, the use of genetic tests may be objected to by
some patients on grounds of religious or ideological
belief or because of the potential impact a result would
have on relatives or decisions to have children. Per-
sonal preferences for trade-offs between over-/under-
diagnosis of a condition, attitudes to risk, and whether
patients’ preferences for body privacy have to be
forgone in undergoing the test are also relevant.
As for assessments of patient experience of diagnostic
services, multiple items are needed to assess each facet of
acceptability.
Good practice in measuring patient
acceptability of specific tests
Tests will be more patient-centred if assessments of
acceptability are embedded into the development cycle of
new tests [15]. This is particularly relevant in the context
of elective diagnosis of conditions where risks are
concentrated in the future, such as in the use of genetic
tests to assess susceptibility for a condition, or the
assessment of premalignant conditions [16, 17]. Test-
specific, and generic measures of test acceptability will
facilitate between-test comparisons and patient choice.
For example, ratings of test acceptability may help pa-
tients with low-risk symptoms of bowel cancer choose
between faecal immunochemical testing (FIT) [18],
sigmoidoscopy, CT colonography or colonoscopy, as a first
test. Of course, informed decision-makingwill also need to
involve information about the clinical utility of the test.
Although there is little evidence supporting (or
refuting) the assertion that test results affect experience [9,
19, 20], the experience of having a positive test relates
greatly to the experience of the diagnosed illness and its
likely treatment and prognosis, therefore it is less relevant
to the acceptability of the test per se.
Unlike the case for measuring the experience of diag-
nostic services, which needs to be repeated periodically, if
the acceptability of a test, to a range of possible test users,
has been validly evaluated during test development, it is
generally unnecessary to repeat such evaluations
routinely. Exceptions may apply to situations where there
is likely to be variation in the intended purpose of the test
or the population undergoing it.
Conclusions
Clinicians, service managers, test developers, and re-
searchers all have a key role to play in ensuring that
patients have a positive experience of diagnostic care,
and that available tests are acceptable as healthcare
Table : Key features of acceptability of tests (based on Sekhon
et al. [], applied to diagnostic testing).
Affective attitude
How the patient feels about the test. A global measure of acceptability
Burden
The perceived amount of effort required to have/do the test and any
resulting side-effects, both physical and psychological
Test coherence
The extent to which the patient understandswhy the test is being done
given their symptoms and context
Perceived test effectiveness
The extent to which the patient believes that the test is likely to
achieve its purpose given their symptoms and context, and give an
accurate result
Self-efficacy
The patient’s confidence that they can complete the test
Financial opportunity costs
The extent to which there are costs associated with having/doing the test
Ethicality
The extent to which the test is a good fit with the patient’s ideological,
religious or political beliefs. Preferences for over/under diagnosis and
whether values have to be forgone to have the test are also pertinent,
along with the potential impact of results on relatives in the case of
genetic testing.
Features are not listed in order of importance. Italics indicates
amendment to the original.
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interventions. We have presented a conceptual guide out-
lining the dimensions that are crucial for evaluations of the
patient experience of diagnostic care and the acceptability
of diagnostic tests, and highlighted contexts in which such
evaluations can result in the greatest improvements to
patient experience. We recommend that:
– the assessment of patient experience of elective diag-
nostic services should be incorporated into routine
patient surveys to support quality improvement ac-
tivities and patient choice;
– to facilitate the assessment of patient experience and test
acceptability, robust survey items, should be developed
using the framework we set out in this paper;
– a comprehensive examination of the patient accept-
ability of specific tests should be embedded into test
development;
– where possible, future evaluations should use com-
parable items assessing experience and acceptability
across tests and health systems to facilitate interna-
tional comparisons and patient choice.
Assessment of patients’ experiences of diagnostic services,
and the degree to which patients find specific tests to be
acceptable, are requisites for enabling services to make
improvements to their diagnostic care quality. Robust as-
sessments can enhance the degree to which we can deliver
patient-centred care, and facilitate patient choice.
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